CRISPR Therapeutics (NasdaqGM:CRSP) COO Departure Announced Following 7% Share Price Decline
CRISPR Therapeutics recently announced the departure of Chief Operating Officer Julianne Bruno, reflecting a notable leadership change that could influence its operational direction. During the past quarter, the company's shares declined by 4.6%, a period marked by a challenging earnings report showing significant revenue drops and increased losses, which likely contributed to the recent share price performance. This downturn occurred amidst wider market concerns, including tariff announcements and broader trade policy uncertainties, which also weighed on investor sentiment, even as major indices such as the S&P 500 saw slight declines.
Buy, Hold or Sell CRISPR Therapeutics? View our complete analysis and fair value estimate and you decide.
AI is about to change healthcare. These 23 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Over the past five years, CRISPR Therapeutics' total shareholder return, including dividends, increased by a modest 1.77%. During this period, the company has faced substantial revenue fluctuations, including a reported revenue drop in 2024, with full-year revenues falling significantly to USD 37.31 million. The volatile revenue pattern was accompanied by substantial net losses, which grew consistently, reaching USD 366.25 million in 2024. Despite some promising product announcements, such as the FDA's RMAT designation for CTX112, these developments have not compensated for the financial pressures evident in recent earnings reports.
Furthermore, CRISPR Therapeutics' performance has been weaker when compared to the broader market, with its one-year return trailing the US Market's 8.5% and the US Biotechs industry's negative returns. The company's ability to generate revenue has been a central concern, as highlighted by an equity offering in February 2024 raising approximately USD 280 million, a potential effort to shore up finances amid ongoing losses.
Click here and access our complete financial health analysis report to understand the dynamics of CRISPR Therapeutics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGM:CRSP.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
an hour ago
- Newsweek
The Key to Better Sleep Is in Your Gut, Says Gastroenterologist
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Around 25 million U.S. adults suffer from insomnia. At the same time, more than 3.9 million Americans are taking probiotics, usually for gut health, according to the American Gastroenterological Association (AGA). And gut health could be the key to better sleep. A study published in the journal Engineering examined a specific probiotic strain called Lactobacillus helveticus CCFM1320. This probiotic produces a compound known as SAM (S-adenosylmethionine), which helps regulate the body's internal clock and supports the production of melatonin, a hormone that promotes sleep. The researchers found that this probiotic could significantly improve sleep quality. The Gut as a Second Brain Neuroscientist Dr. Chelsie Rohrscheib, the head of sleep at Wesper, a national home sleep disorder diagnostics company, told Newsweek: "The gut essentially acts as a secondary nervous system and creates and releases many crucial neurotransmitters, such as serotonin, which also help to regulate nervous system activity. "This allows for two-way communication between the gut and the brain, called the gut-brain axis. Healthy gut microbes are essential to keeping the gut healthy and functioning, and there is ample evidence that gut microbiota dysregulation can negatively impact the activity of the gut-brain axis. Because the brain is highly sensitive, this can lead to poor sleep quality." Stock image of a woman taking pills from her nightstand before bed. Stock image of a woman taking pills from her nightstand before bed. Liudmila Chernetska/iStock / Getty Images Plus Is CCFM1320 a Game-Changing Strain? To test the effectiveness of CCFM1320 in humans, scientists from Jiangnan University conducted a four-week study with 60 volunteers who experienced sleep difficulties. Participants were divided into two groups: one received the probiotic, while the other took a placebo. Results showed that those who consumed the probiotic had better sleep scores, lower levels of the stress hormone cortisol, and a healthier balance of gut bacteria. Additionally, the probiotic boosted the expression of genes involved in producing and utilizing SAM, a key factor in sleep and overall health. Strain-Specific Benefits Dr. Michel Bass, a board-certified gastroenterologist and the Founding Medical Director at Oshi Health in Philadelphia, Pennsylvania, emphasized the importance of strain specificity: "Not all probiotics are created equal. This study identified CCFM1320 as uniquely beneficial for sleep quality. This isn't a generic 'take-any-probiotic' situation—it's about strain-level specificity," Bass told Newsweek. "That's where a lot of public messaging needs to evolve. Just like different medications target different conditions, different strains do different things. And this one appears to enhance melatonin synthesis via SAM methylation—a novel pathway." Probiotic Supplements vs. Fermented Foods Stock image of an assortment of fresh vegetables and meats. Stock image of an assortment of fresh vegetables and meats. esilzengin/iStock / Getty Images Plus While fermented foods like yogurt, kimchi, and kefir are beneficial for general gut health, Bass explained that they may not provide targeted probiotic strains at therapeutic levels. "If someone wants to improve things like sleep quality or reduce stress hormones like cortisol, a strong, well-researched supplement—especially one with proven strains like CCFM1320—is usually more effective," he said. "That said, eating fermented foods is still a great daily habit and can complement targeted probiotic supplements." Jason Eastty, owner of Healthspan Longevity in Westborough, Massachusetts, and a nutrition specialist, added that overall good nutrition can combat poor sleep. "Having a nutrient deficiency—like low iron, magnesium, or vitamin D—can throw off your gut microbial balance, leading to poor sleep. Clinical trials have shown that correcting these deficiencies helps microbial diversity and improves sleep efficiency," Eastty said. He also emphasized that a whole-foods diet rich in fiber—from fruits, vegetables, legumes, nuts, seeds, and whole grains—is essential to feeding the "good" bacteria in your gut.
Yahoo
2 hours ago
- Yahoo
The Vanguard Growth ETF Is a Great Choice for Most, But I Like the Invesco QQQ Trust Better
The Vanguard Growth ETF has been a strong performer over the years. However, the Invesco QQQ Trust's performance has been even better, and its holdings are less top-heavy. That said, investing consistently in these exchange-traded funds is just as important as picking the right one. 10 stocks we like better than Invesco QQQ Trust › The Vanguard Growth ETF (NYSEMKT: VUG) is one of the most popular exchange-traded funds (ETFs) around, and it's a great choice for many investors. The ETF tracks the performance of the CRSP US Large Cap Growth Index, which includes stocks representing the growth side of the S&P 500. Notably, the ETF holds around 166 stocks, while its value counterpart, the Vanguard Value ETF (NYSEMKT: VTV), carries 331 stocks, since fewer large-cap stocks are classified as growth stocks. Stocks will also sometimes bounce between the growth ETF and the value ETF. For example, last year, Broadcom was one of the top stocks in the value index, but it has since shifted to being a top-10 holding in the growth ETF. The Vanguard Growth ETF is very tech-heavy, with such stocks accounting for 58.5% of its portfolio. Its top three -- Microsoft, Nvidia, and Apple -- represent almost 32% of its holdings. Growth and technology stocks have been helping lead the market higher for a long time, which can be seen in the outperformance of the Vanguard Growth ETF compared to both the Vanguard S&P 500 ETF (NYSEMKT: VOO) and the Vanguard Value ETF. Over the past decade, as of the end of May, the Vanguard Growth ETF has produced an average annual return of 15.3% versus 12.8% for the Vanguard S&P 500 ETF and 10% for the Vanguard Value ETF. Overall, the Vanguard Growth ETF is a great option for investors; however, there is one growth-focused ETF I like even more. The Invesco QQQ Trust (NASDAQ: QQQ) has been one of the best-performing non-leveraged or sector-specific ETFs around. This ETF has outperformed both the Vanguard 500 ETF and the Vanguard Growth ETF over the past decade. As of the end of May, it has generated an average annual return of 17.7%, outpacing its rivals. ETF 5-Year Average Annual Return 10-Year Average Annual Return Vanguard Value 13.9% 10% Vanguard S&P 500 15.9% 12.8% Vanguard Growth 17.2% 15.3% Invesco QQQ Trust 18.1% 17.7% Source: Vanguard and Invesco websites. The Invesco QQQ Trust's outperformance against the S&P 500 isn't just due to a couple of big years. It has been able to consistently outdo the benchmark index over the past decade. In fact, during this period, it has outperformed the S&P 500 more than 87% of the time on a rolling-12-month basis. That's impressive. Like the Vanguard Growth ETF, the Invesco QQQ Trust is also heavily weighted toward tech, with 57.2% of its portfolio classified in that sector as of the end of March. However, the Invesco ETF is actually less top-heavy than the Vanguard Growth ETF, with its top three holdings representing less than 25% of its portfolio (versus almost 32% in the Vanguard ETF). While they share many of the same top holdings, they are more spread out in the Invesco QQQ, which is another reason I prefer it. Here are the two ETFs' top 10 holdings and their weightings: Vanguard Growth Weighting Invesco QQQ Weighting 1. Microsoft 11.3% 1. Microsoft 8.8% 2. Nvidia 10.3% 2. Nvidia 8.7% 3. Apple 10.1% 3. Apple 7.3% 4. Amazon 6.3% 4. Amazon 5.6% 5. Alphabet 5.8% 5. Alphabet 5% 6. Meta Platforms 4.4% 6. Broadcom 4.8% 7. Broadcom 4% 7. Meta Platforms 3.8% 8. Tesla 3.3% 8. Netflix 3.2% 9. Eli Lilly 2.2% 9. Tesla 2.9% 10. Visa 2.2% 10. Costco 2.7% Note: VUG holdings are as of May 31, and QQQ holdings are as of June 17. Growth investors can't go wrong with either the Vanguard Growth ETF or the Invesco QQQ Trust, although I prefer the latter due to its track record of outperformance and its currently being less top-heavy. That said, regardless of which ETF you pick, the key to creating long-term wealth will be consistently investing in it using a dollar-cost averaging strategy. In the long run, this is just as important -- or perhaps even more so -- than trying to pick which is the better ETF right now. Before you buy stock in Invesco QQQ Trust, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Invesco QQQ Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Geoffrey Seiler has positions in Alphabet, Invesco QQQ Trust, and Vanguard S&P 500 ETF. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Costco Wholesale, Meta Platforms, Microsoft, Netflix, Nvidia, Tesla, Vanguard Index Funds - Vanguard Growth ETF, Vanguard Index Funds - Vanguard Value ETF, Vanguard S&P 500 ETF, and Visa. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. The Vanguard Growth ETF Is a Great Choice for Most, But I Like the Invesco QQQ Trust Better was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Marathon Digital Holdings, Inc. (MARA) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Marathon Digital Holdings, Inc. (MARA) closed at $14.32, marking a -1.17% move from the previous day. This change lagged the S&P 500's daily loss of 0.22%. Elsewhere, the Dow gained 0.08%, while the tech-heavy Nasdaq lost 0.51%. Shares of the company have depreciated by 7.41% over the course of the past month, underperforming the Finance sector's loss of 1.59%, and the S&P 500's gain of 0.45%. The investment community will be paying close attention to the earnings performance of Marathon Digital Holdings, Inc. in its upcoming release. The company is expected to report EPS of -$0.42, down 75% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $212.57 million, reflecting a 46.46% rise from the equivalent quarter last year. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$1.77 per share and a revenue of $883.79 million, indicating changes of -202.91% and +34.65%, respectively, from the former year. Investors should also take note of any recent adjustments to analyst estimates for Marathon Digital Holdings, Inc. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 27.8% higher. As of now, Marathon Digital Holdings, Inc. holds a Zacks Rank of #4 (Sell). The Financial - Miscellaneous Services industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 143, which puts it in the bottom 42% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Marathon Digital Holdings, Inc. (MARA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
